Japan Unit Of AstraZeneca Begins Second-Phase Trials For Lupus Drug
This article was originally published in PharmAsia News
Executive Summary
The Japanese unit of U.K.-based AstraZeneca says it has begun Phase II trials of its MEDI-545 (sifalimumab) drug for treating lupus. The treatment being tested by AstraZeneca KK relies on supplying an antibody for interferon alpha considered to be the cause of lupus in high concentrations. Another AstraZeneca subsidiary, U.S.-based Medimmune, created the drug in 2004 and is developing it through its subsidiaries in Japan, Europe and the United States. (Click here for more - a subscription may be required